Verrica Pharmaceuticals earnings release, May 12, 2026

Verrica Pharmaceuticals Inc. (VRCA) · Form 8-K, Item 2.02 · Filed · SEC filing

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results – Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed applicator units since launch – – Company announces achievement of over 50% of current targeted enrollment in the first trial in global Phase 3 common warts program and expects to initiate the second trial in the US and Japan in mid-2026 – – Company reports total revenue of $5.0 million in Q1 2026, including U.S. YCANTH net product revenue of $4.3 million in Q1 2026, up 16.2% over previous quarter and 25.4% year-over-year – – YCANTH commercial launch in Japan by partner

Torii Pharmaceutical represents expansion into first ex-U.S. market – – Company continues preparation for Phase 3 study of

VP-315 in basal cell carcinoma – – Conference call scheduled for today, May 12, 2026, at 4:30 pm ET – WEST CHESTER, PA – May 12, 2026 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced financial results for the first quarter ended March 31, 2026.

“Our first quarter performance reflects accelerating growth in market demand for YCANTH as the new standard of care for the treatment of molluscum contagiosum, a condition that impacts approximately 6 million people in the United States alone,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “As the only

FDA-approved,

HCP-administered therapy for molluscum, YCANTH is a product that is uniquely positioned to address the unmet need of patients with molluscum, largely children under the age of 14. Demand for YCANTH grew sharply during the first quarter, as we set new records for dispensed applicator units during the quarter and in the month of March. April dispensed applicator units increased further from the record total in March, and the Company has achieved the milestone of over 100,000 total dispensed applicator units since launch. We have also achieved another significant milestone in expanding to new markets as our partner, Torii Pharmaceutical, launched YCANTH in Japan for patients with molluscum following regulatory approval last year.”

“We are beginning to realize the traction from the efforts we began to implement last year to stabilize and grow our business. Alongside the growth in demand for YCANTH, we believe Verrica’s future growth is enhanced by the potential of our late-stage clinical programs in basal cell carcinoma and common warts, which we believe could represent multi-billion dollar opportunities if these programs successfully complete their development and are approved,” Dr. Rieger continued. “The exciting data from the Phase 2 study of our novel oncolytic peptide,

VP-315, for the treatment of basal cell carcinoma is generating strong interest within the dermatology and oncology communities and among patients faced with treating basal cell carcinoma. Further, last December the first patient was dosed in the first trial

(COVE-2) of the global Phase 3 program evaluating YCANTH

(VP-102) for the treatment of common warts, and we are happy to announce achievement of over 50% of the current targeted enrollment in the trial. We expect the second Phase 3 trial

(COVE-3) in the common warts program, with sites in both the U.S. and Japan, will be initiated in mid-2026.

If successful, the global Phase 3 program in common warts has the potential to greatly expand the market for YCANTH to an indication with an estimated 22 million patients in the

United States. The efforts we are undertaking in commercializing YCANTH for molluscum lay the foundation for an efficient and rapid expansion into common warts, if approved, as there will be a significant overlap in the clinicians treating both indications who would have the ability to access the product for both patient populations through the same distribution channels.”

Dr. Rieger concluded, “we are proud of our progress in establishing YCANTH as the new standard of care for molluscum and of our work to expand our products, indications and markets. Collectively, our commercially available asset and pipeline programs, if successful, could represent significant benefits for patients and value for our company and our shareholders.”

Conference Call and Webcast

Information

The Company will host a conference call on Tuesday, May 12, 2026, at 4:30 pm, to discuss its first quarter 2026 financial results and provide a business update. To participate in the conference call, please utilize the following information:

Domestic

Dial-In

Number: Toll-Free:

1-833-316-2483

International

Dial-In

Number:

1-785-838-9284

Conference ID: VERRICA

Participants can use Guest dial-in

#s above and be answered by an operator.

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1758586&tp_key=307852c58b

The call will be broadcast live over the Web and can also be accessed on Verrica Pharmaceuticals’ website: www.verrica.com.

The conference call will also be available for replay for one month on the Company’s website in the

Events Calendar of the Investors section.

Business Highlights and Recent Developments

YCANTH®

(VP-102)

VP-315

CORPORATE

First Quarter 2026 Financial Results

Non-GAAP

Financial Measures

In evaluating the operating performance of its business, Verrica’s management considers non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share.

These non-GAAP financial measures exclude stock-based compensation expense and non-cash interest expense that are required by GAAP. Verrica excludes non-cash stock-based compensation..ense from these non-GAAP measures to facilitate comparison to peer companies who also provide similar non-GAAP disclosures and because it reflects how management internally manages the business. In addition, Verrica excludes non-cash interest expense from these non-GAAP measures to facilitate an understanding of the effects of the debt service obligations on the Company’s liquidity and comparisons to peer group companies who also provide similar non-GAAP disclosures and because it is reflective of how management internally manages the business. Verrica also excludes certain other one-time expenses and impacts from change in fair value of derivative liability.

Non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share have been reconciled to the nearest GAAP measure in the tables following the financial statements in this press release.

About YCANTH®

(VP-102)

YCANTH® is a proprietary drug-device combination product that contains a

GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum. Approximately 250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay just $25 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information.

About

VP-315

(ruxotemitide)

VP-315 is a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death and thereby unleashing a broad spectrum of tumor antigens for T cell responses, which may offer a non-surgical option for patients suffering from skin cancer. The technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Verrica holds an exclusive worldwide license to develop and commercialize

VP-315 for certain dermatologic oncology indications, including non-metastatic melanoma and non-metastatic merkel cell carcinoma, and intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development.

VP-315 has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncology trials.

About Verrica Pharmaceuticals Inc.

Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH®

(VP-102)

(cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH®

(VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize

VP-315

(ruxotemitide, formerly known as

LTX-315 and

VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

Financial statements

Income Statement

Three Months Ended March 31, — (in thousands except share and per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
RevenueProduct revenue, net4,2903,422
RevenueLicense and Collaboration revenue73317
RevenueTotal revenue5,0233,439
Operating Expenses:Cost of product revenue544423
Operating Expenses:Cost of collaboration revenue34514
Operating Expenses:Selling, general and administrative9,9898,848
Operating Expenses:Research and development3,8602,284
Operating Expenses:Total expenses14,73811,569
Operating Expenses:Loss from operations-9,715-8,130
Operating Expenses:Interest income201337
Operating Expenses:Interest expense-160-2,203
Operating Expenses:Change in fair value of derivative liability254
Operating Expenses:Other expense-8
Operating Expenses:Net loss-9,682-9,742
Net loss per shareBasic and diluted-0.45-1.03
Weighted average common shares outstandingBasic and diluted21,305,0259,483,734

Income Statement

Three Months Ended March 31, 2026 — (in thousands, except share and per share data)

Three Months Ended March 31, 2026 – Loss from OperationsThree Months Ended March 31, 2025 – Loss from OperationsThree Months Ended March 31, 2026 – Net lossThree Months Ended March 31, 2025 – Net lossThree Months Ended March 31, 2026 – Net loss per share (basic and diluted)Three Months Ended March 31, 2025 – Net loss per share
GAAP-9,715-9,682-0.45
Non-GAAP Adjustments:Stock-based compensation - Selling, General & Admin (a)5935930.03
Non-GAAP Adjustments:Stock-based compensation - Research & Development (a)2762760.01
Non-GAAP Adjustments:Stock-based compensation - Cost of Product (a)14140
Non-GAAP Adjustments:Stock-based compensation - Cost of Collaboration (a)14140
Non-GAAP Adjustments:Adjusted-8,818-8,785-0.41
Non-GAAP Adjustments:GAAP-8,130-9,742-1.03
Non-GAAP Adjustments:Stock-based compensation - Selling, General & Admin (a)7857850.08
Non-GAAP Adjustments:Stock-based compensation - Research & Development (a)2412410.03
Non-GAAP Adjustments:Derivative liability change in value (b)-254-0.03
Non-GAAP Adjustments:Non-cash interest expense (b)6680.07
Non-GAAP Adjustments:Adjusted-7,104-8,302-0.88

Balance Sheet

December 31, — (in thousands)

March 31, – 2026December 31, – 2025
Cash20,60030,147
Accounts receivable7,8135,397
Deferred R&D services, current portion1,3741,958
Inventory1,9742,236
Prepaid expenses and other assets2,3682,801
Total current assets34,12942,539
Deferred R&D services, non-current portion2,3542,354
PP&E, Lease right-of-use asset, other2,3032,238
Total assets38,78647,131
Current Liabilities16,91717,322
R&D funding liability5,8145,066
Total liabilities22,73122,388
Total stockholders’ equity16,05524,743
Total Liabilities & Stockholders’ Equity38,78647,131
Full release

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as

“believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the commercialization of YCANTH, the clinical development and benefits of Verrica’s product candidates, including YCANTH

(VP-102) and

VP-315, the development and regulatory plans for YCANTH, and the timing of initiating the second Phase 3 study of YCANTH for common warts. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, and other risks and uncertainties that are described in Verrica’s Annual Report on Form

10-K for the year ended December 31, 2025, Verrica’s Quarterly Reports on Form

10-Q and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

VERRICA PHARMACEUTICALS INC.

Selected Statements of Operations Data

(in thousands except share and per share data)... CA PHARMACEUTICALS INC.

Selected Balance Sheets Data

(in thousands)

VERRICA PHARMACEUTICALS INC.

Reconciliation of

Non-GAAP

Financial Measures (unaudited)

(in thousands, except share and per share data)

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John Kirby

Interim Chief Financial Officer jkirby@verrica.com

Kevin Gardner

LifeSci Advisors kgardner@lifesciadvisors.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Verrica Pharmaceuticals earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.